Premenstrual Dysphoric Disorder Market By Drug Phase | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Premenstrual Dysphoric Disorder Market
Premenstrual Dysphoric Disorder Market: By Drug Phase (Clinical Trial Phase 1, Clinical Trial Phase 2, Clinical Trial Phase 3 and Launched) & By Geography - Forecast (2016-2021)
Report Code : HCR 0266
Published: 26 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Premenstrual dysphoric disorder (PMDD) is a medical condition in which a woman undergoes severe depression symptoms, irritability, and tension before menstruation cycle. These symptoms of premenstrual dysphoric disorder are more severe than those seen with premenstrual syndrome (PMS). Some of the major factors playing important role for the PMDD are alcohol or substance abuse, thyroid disorders, being overweight, having a mother with a history of the disorder and lack of exercise. Some of the common symptoms of PMDD are anxiety, out of control feeling, food cravings or binge eating, mood swings with bouts of crying and panic attacks, bloating, breast tenderness, headaches, and joint or muscle pain, problems sleeping, trouble concentrating. Globally increasing awareness and registered cases of PMDD are expected to drive the demand for the PMDD market however regulations over the usage of such medicines in some of the nations  and higher R&D cost involved to develop new drugs and treatments is expected to be the key constraints during the period of study.

This report identifies the global premenstrual dysphoric disorder market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to premenstrual dysphoric disorder market.
 
Premenstrual Dysphoric Disorder Market

Geographically, North America dominated the premenstrual dysphoric disorder market due to higher awareness about such diseases, higher registered cases due to life style related health issues and well developed healthcare infrastructure. North America was followed by Europe and Asia-Pacific as the second and third largest consumer of premenstrual dysphoric disorder. Asia Pacific is projected to have the fastest growth, owing to rapidly expanding healthcare infrastructure, increasing awareness especially in the major regional economies such as India and China in the region. 

This report segments premenstrual dysphoric disorder market on the basis of clinical trial phase and regional market as follows:

  • On the basis of clinical trial phase this report on premenstrual dysphoric disorder market is segmented as follows, covering major segments as follows: Clinical Trial Phase 1, Clinical Trial Phase 2, Clinical Trial Phase 3, and commercially Launched
  • This report on premenstrual dysphoric disorder has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the premenstrual dysphoric disorder market. Some of the major companies’ profiles in detail are as follows:
  • Bristol Meyer Squibb
  • Merck and Co.
  • Novartis AG
  • Pfizer, Inc.
  • Cipla Laboratories.
1. Premenstrual Dysphoric Disorder Market –  Overview
2. Executive Summary 
3. Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Premenstrual Dysphoric Disorder Market– Forces
   4.1. Drivers
      4.1.1. Growing registered cases of PMDD due to changing life style
   4.2. Restraints
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Premenstrual Dysphoric Disorder Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life cycle Analysis
   5.5. Suppliers & Distributors
6. Premenstrual Dysphoric Disorder Market, By Clinical Trial Phase
   6.1. Clinical Trial Phase 1
   6.2. Clinical Trial Phase 2
   6.3. Clinical Trial Phase 3
   6.4. Commercially Launched
7. Premenstrual Dysphoric Disorder Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America 
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Premenstrual Dysphoric Disorder – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   9.1. Bristol Meyer Squibb
   9.2. Merck and Co.
   9.3. Novartis AG
   9.4. Pfizer, Inc.
   9.5. Cipla Laboratories
   9.6. GlaxoSmithKline plc
   9.7. Johnson & Johnson
   9.8. Abbott Healthcare
   9.9. Eli Lilly and Company
   9.10. Dr. Reddy’s Laboratories Ltd.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibiliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll